Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002
Patterns of Disease Activity in Multiple Sclerosis:Clinical and Magnetic Resonance Imaging Study
BMJ 300:631-634, Thompson,A.J.,et al, 1990
MRI Features of Benign Multiple Sclerosis: Toward a New Definition of This Disease Phenotype
Neurol 72:1693-1701, Rovaris,M.,et al, 2009
Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-Up Study
Ann Neurol 56:303-306, Pittock,S.J.,et al, 2004
Neurologic Impairment 10 Years After Optic Neuritis
Arch Neurol 61:1386-1389, Optic Neuritis Study Group, 2004
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Multiple Sclerosis That is Progressive From the Time of Onset, Clinical Characteristics and Progression of Disability
Arch Neurol 56:1138-1142, Andersson,P.B.,et al, 1999
Association Between Tumor Necrosis Factor-x and Disease Progression in Patients with Multiple Sclerosis
NEJM 325:467-472, Shareif,M.K.&Hentges,R., 1991
Multiple Sclerosis After Age 50
Neurol 33:1537-1544, Noseworthy,J.,et al, 1983
The prognosis of Multiple Sclerosis
Editorial, BMJ 281:824-8251980., , 1980